Regulators take softer approach to Ranbaxy plant
This article was originally published in Scrip
Executive Summary
Drug regulators around the world, including the World Health Organization, are not taking the same strong line on Ranbaxy's Paonta Sahib manufacturing plant, after the US FDA accused the Indian firm of falsifying data and test results.